Osteonic Co. Ltd (226400) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Osteonic Co. Ltd KRW 7,344, price KRW 3,980, upside +84.5%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Osteonic Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 2,340 KRW – 8,390 KRW · fair‑value band 3,583 KRW – 9,222 KRW · the 3,980 KRW price screens below the 7,344 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Osteonic Co. in your weekly email
Every Wednesday you see whether Osteonic Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Osteonic Co., Ltd. develops, manufactures, and sells bone fixation systems.
Show more
Osteonic Co., Ltd. develops, manufactures, and sells bone fixation systems. It offers CMF systems, including neuro plating systems, maxillofacial plating systems, mandible plating systems, IMF screws, power screw drivers, 90 angled screw driver, customized neuro 3D mesh, and mandible reconstruction plates under the OPTIMUS and Real FIT brand names; and biodegradable CMF plating systems under the BIOBSORB name. The company also provides products for trauma and extremities, which include hand plating, wrist plating, foot plating, and hallux valgus systems, as well as cannulated screws under the SIGNEX name. In addition, it offers dental products, such as mini screws, GBR systems, palatal plates, power drivers, and palatal expanders under the Optimus D name; veterinary systems; and sports medicines under the KINEX brand name. The company serves physicians and university hospitals. Osteonic Co., Ltd. was founded in 2012 and is based in Seoul, South Korea.
Stock analysis
Osteonic Co. Ltd (226400) currently trades at 3,980 KRW, while our model-based Fair Value estimate is 7,344 KRW, implying the stock looks roughly 45.8% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 13,006 KRW per share, and 17 of the 23 models we run sit above the 3,980 KRW price.
Bear case: the Growth DCF group reads lowest at 1,432 KRW, and 6 of the 23 models stay below the price. Evidence for this calculation is medium.
Scenario range: 3,583 KRW (bear) to 9,222 KRW (bull), the price of 3,980 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Osteonic Co. Ltd reported revenue of 45.4B KRW in FY2025 versus 15.6B KRW in FY2021, a compound +30.6%/yr. Reported net income was 7.5B KRW in FY2025.
Key figures
Market cap 90.3B KRW (≈ $66.3M) · P/S ratio 1.85 · Net margin 16.5% · Return on equity 14.3% · Return on assets (EBIT) 5.2% · Operating margin 18.1% · Revenue (TTM) 48.8B KRW · Revenue growth (YoY) +35.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 50% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 85%, 226400 screens cheaper than that median.
Fair Value models
Bear 3,583 KRWFair Value 7,344 KRWBull 9,222 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.2%
Start year 2020 (pandemic). Over 10 years: +29.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+73.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+73.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.57% vs 7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−20% → 20%
2025 sits 102% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside+85% · Top 25%
Profitability
Return on equity (TTM)14% · Top 25%
Return on assets6% · Top 25%
Net margin (TTM)19% · Top 25%
Operating margin (TTM)18% · Top 25%
Growth and dividend
Revenue growth35% · Top 25%
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Osteonic Co. Ltd (226400) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 7,344 KRW versus a price of 3,980 KRW, about +85% upside (undervalued).
What is the fair value of 226400?
Our model-based fair value for Osteonic Co. Ltd is 7,344 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,980 KRW.
What is the quality score of 226400?
Osteonic Co. Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Osteonic Co. Ltd (226400)?
Our model-based price target is the fair value of 7,344 KRW (as of Sep 24, 2026) from 23 valuation models. Cautious scenario 3,583 KRW, optimistic scenario 9,222 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Osteonic Co. Ltd stock forecast for 2026?
Our models put fair value at 7,344 KRW, about +85% upside versus a price of 3,980 KRW (undervalued). Cautious scenario 3,583 KRW, optimistic scenario 9,222 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Osteonic Co. Ltd (226400)?
Osteonic Co. Ltd reported trailing-twelve-month revenue of about 48.8B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Osteonic Co. Ltd (226400)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Osteonic Co. Ltd it is 7,344 KRW per share (as of Sep 24, 2026), against a price of 3,980 KRW. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Osteonic Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 226400 trades below its calculated fair value: price 3,980 KRW, fair value 7,344 KRW, a gap of about +85% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 226400?
No. The price is what the market pays today (3,980 KRW); the fair value is what the company's own numbers justify (7,344 KRW). For Osteonic Co. Ltd the two are 3,364 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Osteonic Co. Ltd worth?
The market values Osteonic Co. Ltd at about 90.3B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,980 KRW; our models calculate a fair value of 7,344 KRW per share.
What do the bullish and bearish scenarios say about 226400?
Our models span a range for Osteonic Co. Ltd: cautious scenario 3,583 KRW, base 7,344 KRW, optimistic 9,222 KRW per share (as of Sep 24, 2026, price 3,980 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Osteonic Co. Ltd (226400)?
Balance-sheet figures for Osteonic Co. Ltd (as of Sep 24, 2026): return on equity 14.3%, debt of 0.06 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 226400 from its 52-week high?
Osteonic Co. Ltd trades at 3,980 KRW, about 50% below its 52-week high of 7,940 KRW and 6% above the low of 3,745 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 7,344 KRW is for.
Which stocks are comparable to Osteonic Co. Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Osteonic Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 3,980 KRW, calculated fair value 7,344 KRW (+85%), Quality Score 47/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 226400 calculated?
We run Osteonic Co. Ltd through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 7,344 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Osteonic Co. Ltd currently trades 85 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Osteonic Co. Ltd (226400)?
The closing price on Sep 23, 2026 was 3,980 KRW. Our model-based fair value is 7,344 KRW, about +85% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Osteonic Co. Ltd right now?
Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (3,583 KRW to 9,222 KRW) leaves room in how you read the outcome.
Key figures of Osteonic Co. Ltd
How large is the market capitalisation of Osteonic Co. Ltd (226400)?
The market capitalisation of Osteonic Co. Ltd is 90.3B KRW (≈ $66.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Osteonic Co. Ltd (226400)?
The price-to-sales ratio of Osteonic Co. Ltd is 1.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Osteonic Co. Ltd (226400)?
The net margin of Osteonic Co. Ltd is 16.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Osteonic Co. Ltd (226400)?
The return on equity (ROE) of Osteonic Co. Ltd is 14.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Osteonic Co. Ltd (226400)?
On an EBIT basis the return on assets of Osteonic Co. Ltd is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Osteonic Co. Ltd (226400)?
The operating margin of Osteonic Co. Ltd is 18.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Osteonic Co. Ltd (226400)?
Revenue at Osteonic Co. Ltd is growing +35.4% versus a year earlier (3y avg +31.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Osteonic Co. Ltd (226400)?
Earnings per share at Osteonic Co. Ltd are growing +242% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Osteonic Co. Ltd (226400) generate?
The free cash flow of Osteonic Co. Ltd is 65.1M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Osteonic Co. Ltd (226400) carry?
The net debt of Osteonic Co. Ltd is 3.4B KRW (fiscal year 2025, ≈ 51.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Osteonic Co. Ltd in the live analysis
One click puts Osteonic Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
